merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Significant safety risks, including swelling and bleeding in the brain</answer>

<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for potentially better treatments</answer>

<question_number>3</question_number>
<answer>No correlation between amyloid plaque removal and clinical response in individual subjects</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>Patients can stop Kisunla after amyloid is cleared, potentially reducing overall cost</answer>

<question_number>6</question_number>
<answer>It might discourage patients from participating in trials for treatments that could be better</answer>

<question_number>7</question_number>
<answer>Kisunla is given monthly, while Leqembi is given every two weeks</answer>

<question_number>8</question_number>
<answer>Amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>Patients with intermediate tau levels declined more slowly on donanemab than those with high levels</answer>